CX-5461 induces cytosolic DNA buildup and STING activation, initiating a type I interferon response. It has potential to enhance immune responses and sensitize chemoresistant ovarian cancer cells to immunotherapy when combined with checkpoint inhibitors. This evidence concerns the gene STING1 and ovarian cancer.